<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116085</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-214</org_study_id>
    <nct_id>NCT05116085</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer</brief_title>
  <official_title>A Single-Arm, Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Early-Stage (Stage II-III) Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, and tolerability of neo-adjuvant treatment with&#xD;
      tislelizumab in participants with early-stage (Stage II-III) Microsatellite Instability-High&#xD;
      (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response (MPR) rate</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>MPR rate is defined as the percentage of participants with â‰¤ 10% residual viable tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>Percentage of participants with absence of residual tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>approximately 50 months</time_frame>
    <description>Time from first dose until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year/3-year EFS rate</measure>
    <time_frame>approximately 50 months</time_frame>
    <description>Percentage of participants free from EFS events at 2 years and 3 years estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Values</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>Laboratory parameters include hematology , chemistry, coagulation and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Signs</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>Vital signs include pulse rate and blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Findings</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>A full physical examination includes head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>approximately 16 months</time_frame>
    <description>Number of participants with one or more TEAE, including serious adverse events and immune-mediated adverse events, graded according to NCI-CTCAE Version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Tislelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab administered intravenously before surgery during the neo-adjuvant phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Tislelizumab</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG Performance status of 0 or 1.&#xD;
&#xD;
          2. Pathologically (histologically) confirmed diagnosis of potentially resectable Stage II&#xD;
             or Stage III CRC with MSI-H confirmed by sponsor designated central laboratory.&#xD;
             Participants should be eligible for an R0 resection with curative intent.&#xD;
&#xD;
          3. Evaluable or measurable disease as assessed by the investigator per RECIST v1.1.&#xD;
&#xD;
          4. Adequate hematologic and organ function, defined by protocol-specified laboratory test&#xD;
             results, obtained within 14 days before first dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior therapy for current CRC, including chemotherapy or radiotherapy or&#xD;
             immunotherapy.&#xD;
&#xD;
          2. Any condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone or equivalent) or other immunosuppressive medications within 14 days before&#xD;
             first dose.&#xD;
&#xD;
          3. Active autoimmune diseases or history of autoimmune diseases that may relapse.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>ClinicalTrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

